Lucid Diagnostics (Lucid Diagnostics) FCF Yield % : -73.66 (As of May. 03, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lucid Diagnostics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Lucid Diagnostics's Trailing 12-Month Free Cash Flow is $-33.04 Mil, and Market Cap is $44.85 Mil. Therefore, Lucid Diagnostics's FCF Yield % for today is -73.66%.

The historical rank and industry rank for Lucid Diagnostics's FCF Yield % or its related term are showing as below:

LUCD' s FCF Yield % Range Over the Past 10 Years
Min: -114.21 Med: -47.17 Max: -1.94
Current: -73.66

During the past 5 years, the highest FCF Yield % of Lucid Diagnostics was -1.94%. The lowest was -114.21%. And the median was -47.17%.

LUCD's FCF Yield % is ranked worse than
90.06% of 865 companies
in the Medical Devices & Instruments industry
Industry Median: -2.62 vs LUCD: -73.66

Lucid Diagnostics's FCF Margin % for the quarter that ended in Dec. 2023 was -976.35%.

Lucid Diagnostics FCF Yield % Historical Data

The historical data trend for Lucid Diagnostics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucid Diagnostics FCF Yield % Chart

Lucid Diagnostics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

-9.88

-55.52

-55.35

Lucid Diagnostics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial											-32.38	-48.32	-48.32	-71.03	-68.05

Competitive Comparison of Lucid Diagnostics's FCF Yield %

For the Medical Devices subindustry, Lucid Diagnostics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lucid Diagnostics's FCF Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Lucid Diagnostics's FCF Yield % falls into.

Lucid Diagnostics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Lucid Diagnostics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-33.038	/	59.685159
	=	-55.35%

Lucid Diagnostics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-10.154	*	4	/	59.685159
	=	-68.05%

Lucid Diagnostics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Lucid Diagnostics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Lucid Diagnostics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lucid Diagnostics (Lucid Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucid Diagnostics Inc (NAS:LUCD) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

360 Madison Avenue, 25th Floor, New York, NY, USA, 10017

Website

https://www.luciddx.com

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Executives

Stanley Lapidus	director	101 HARTWELL AVE., LEXINGTON MA 02421
Debra White	director	C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Michael Adam Gordon	officer: General Counsel	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Shaun O'neil	officer: Chief Operating Officer	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Pavmed Inc.	10 percent owner	360 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10017
Lishan Aklog	director, officer: Chief Executive Officer	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Dennis M Mcgrath	officer: Chief Financial Officer	C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Ronald M Sparks	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
James L Cox	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Aster Angagaw	director	150 PEABODY PLACE, MEMPHIS TN 38103
Jacque J Sokolov	director
David F Wurtman	officer: Chief Medical Officer	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165